PATRICIO LOPEZ -JARAMILLO

Cited by

	All	Since 2019
Citations	137794	71525
h-index	109	90
i10-index	374	287

15000

7500

3750

11250

20052006200720082009201020112012201320142015201620172018201920202021202220232024352 510 667 699 734 1158 2486 3727 5313 6600 7998 9616 10631 12221 13633 14054 14168 13503 12309 3600

Public access

View all

156 articles

14 articles

available

not available

Based on funding mandates

Co-authors

Salim YusufPopulation Health Research Institute, McMaster University and Hamilton Health SciencesVerified email at mcmaster.ca
Ronald G GarciaDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical SchoolVerified email at nmr.mgh.harvard.edu
Diego Gomez-ArbelaezMASIRA Research Institute, Universidad de Santander (UDES)Verified email at mail.udes.edu.co
Prof. Denis Xavier MD, MScVice Dean (PG), Professor Pharmacology, Head, Div of Clinical Research, St. John's Medical CollegeVerified email at sjri.res.in
Antonio DansCollege of Medicine, University of the PhilippinesVerified email at up.edu.ph
JP Casas, MD, PhDBiomarker Development / Translational Medicine. Novartis Institute for Biomed ResearchVerified email at novartis.com
Shofiqul Islam, PhDPopulation Health Research Institute, McMaster UniversityVerified email at phri.ca
Johanna OteroUniversidad de Santander (UDES)Verified email at udes.edu.co
Enrique TeranUniversidad San Francisco de QuitoVerified email at usfq.edu.ec
Scott LearFaculty of Health Sciences, Simon Fraser UniversityVerified email at providencehealth.bc.ca
Graeme J. HankeyWInthrop Professor of Neurology, The University of Western Australia; Neurologist, Sir CharlesVerified email at uwa.edu.au
Professor Jephat ChifambaUniversity of ZimbabweVerified email at medic.uz.ac.zw
Darryl P. LeongThe Population Health Research Institute, McMaster University and Hamilton Health SciencesVerified email at phri.ca
Roya KelishadiProfessor of Pediatrics, Isfahan University of Medical SciencesVerified email at med.mui.ac.ir
Camilo FélixProfesor de Farmacología, Universidad UTE, EcuadorVerified email at ute.edu.ec
Paul Anthony Camacho LopezFundación Oftalmológica de Santander - Universidad Autónoma de BucaramangaVerified email at foscal.com.co
Martin McKeeProfessor of European Public Health, London School of Hygiene and Tropical MedicineVerified email at lshtm.ac.uk
Omar Rahman (ORCID:0000-0002-06...Dean of Research, University of Liberal Arts BangladeshVerified email at ulab.edu.bd
Marcos LopezUniversity of Puerto Rico at HumacaoVerified email at upr.edu
Aletta E SchutteUniversity of New South Wales/George Institute for Global HealthVerified email at unsw.edu.au

PATRICIO LOPEZ -JARAMILLO

Scientific Director Masira Research Institute, UDES,Bucaramanga,Colombia,Vist Prof, UTE,Ecuador

Verified email at ute.edu.ec

enfermedades cardiometabolicas


Title Sort by citations Sort by year Sort by title	Cited by Cited by	Year
Heart disease and stroke statistics—2016 update: a report from the American Heart Association D Mozaffarian, EJ Benjamin, AS Go, DK Arnett, MJ Blaha, M Cushman, ... circulation 133 (4), e38-e360, 2016	75823*	2016
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study MJ O'donnell, D Xavier, L Liu, H Zhang, SL Chin, P Rao-Melacini, ... The Lancet 376 (9735), 112-123, 2010	4261	2010
Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries CK Chow, KK Teo, S Rangarajan, S Islam, R Gupta, A Avezum, ... Jama 310 (9), 959-968, 2013	2393*	2013
Rivaroxaban with or without aspirin in stable cardiovascular disease JW Eikelboom, SJ Connolly, J Bosch, GR Dagenais, RG Hart, ... New England Journal of Medicine 377 (14), 1319-1330, 2017	2348	2017
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 121-130, 2019	2225	2019
Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study MJ O'Donnell, SL Chin, S Rangarajan, D Xavier, L Liu, H Zhang, ... The lancet 388 (10046), 761-775, 2016	2126	2016
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021	1967*	2021
Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study DP Leong, KK Teo, S Rangarajan, P Lopez-Jaramillo, A Avezum, ... The lancet 386 (9990), 266-273, 2015	1766	2015
Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort … S Yusuf, P Joseph, S Rangarajan, S Islam, A Mente, P Hystad, M Brauer, ... The Lancet 395 (10226), 795-808, 2020	1330	2020
The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study SA Lear, W Hu, S Rangarajan, D Gasevic, D Leong, R Iqbal, A Casanova, ... The Lancet 390 (10113), 2643-2654, 2017	1283	2017
Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study M Dehghan, A Mente, X Zhang, S Swaminathan, W Li, V Mohan, R Iqbal, ... The Lancet 390 (10107), 2050-2062, 2017	1176	2017
Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective … S Yusuf, S Islam, CK Chow, S Rangarajan, G Dagenais, R Diaz, R Gupta, ... The Lancet 378 (9798), 1231-1243, 2011	1076	2011
Cardiovascular risk and events in 17 low-, middle-, and high-income countries S Yusuf, S Rangarajan, K Teo, S Islam, W Li, L Liu, J Bo, Q Lou, F Lu, ... New England Journal of Medicine 371 (9), 818-827, 2014	1053	2014
Urinary sodium and potassium excretion, mortality, and cardiovascular events M O'Donnell, A Mente, S Rangarajan, MJ McQueen, X Wang, L Liu, H Yan, ... New England Journal of Medicine 371 (7), 612-623, 2014	1024	2014
Cholesterol lowering in intermediate-risk persons without cardiovascular disease S Yusuf, J Bosch, G Dagenais, J Zhu, D Xavier, L Liu, P Pais, ... New England Journal of Medicine 374 (21), 2021-2031, 2016	1002	2016
Association of urinary sodium and potassium excretion with blood pressure A Mente, MJ O'Donnell, S Rangarajan, MJ McQueen, P Poirier, ... New england journal of medicine 371 (7), 601-611, 2014	964	2014
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial SS Anand, J Bosch, JW Eikelboom, SJ Connolly, R Diaz, P Widimsky, ... The Lancet 391 (10117), 219-229, 2018	923	2018
A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension MH Olsen, SY Angell, S Asma, P Boutouyrie, D Burger, JA Chirinos, ... The Lancet 388 (10060), 2665-2712, 2016	877	2016
Blood-pressure lowering in intermediate-risk persons without cardiovascular disease EM Lonn, J Bosch, P López-Jaramillo, J Zhu, L Liu, P Pais, R Diaz, ... New England Journal of Medicine 374 (21), 2009-2020, 2016	786	2016
Is C-reactive protein an independent risk factor for essential hypertension? LE Bautista, P López-Jaramillo, LM Vera, JP Casas, AP Otero, ... Journal of hypertension 19 (5), 857-861, 2001	656	2001

The system can't perform the operation now. Try again later.

Articles 1–20

Citations per year

Duplicate citations

Merged citations

Add co-authorsCo-authors

Follow

Cited by

Co-authors